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In early drug development advanced imaging techniques can help with progressing new molecular entities (NME) to subsequent
phases of drug development and thus reduce attrition. However, several organizational, operational, and regulatory hurdles pose
a significant barrier, potentially limiting the impact these techniques can have on modern drug development. Positron emission
tomography (PET) of radiolabelled NME is arguably the best example of a complex technique with a potential to deliver unique
decision-making data in small cohorts of subjects. However, to realise this potential the impediments to timely inclusion of PET
into the drug development process must be overcome. In the present paper, we discuss the value of PET imaging with radiolabelled
NME during early anticancer drug development, as exemplified with one such NME. We outline the multiple hurdles and propose
options on how to streamline the organizational steps for future studies.
1. Background
Access to and achieving therapeutic drug levels in the target
tissue are a basic prerequisite for the successful development
of a new molecular entity (NME). Conventionally, in drug
development, plasma drug pharmacokinetics supplemented
by preclinical data relating plasma to tissue pharmacokinetics
is used as surrogate for target pharmacokinetics. However,
increased realisation about interspecies differences and vari-
able drug access in tumours and in sanctuary tissue sites,
such as the brain, has led to the exploration of other methods
that can provide confidence in tissue drug biodistribution and
kinetics. One methodology that can provide such supportive
information noninvasively is positron emission tomography
(PET) imaging of radiolabelled NMEs. Radiolabelling of
NME with a positron-emitting radionuclide to enable imag-
ing does not change its biochemical properties and allows
quantification of the NME at picomolar levels in vivo in
tissue [1]. PET imaging continues to be used broadly in
neurosciences to evaluate drug access to the target during
early stages of clinical development [2, 3]. In oncology, PET
imaging studies can provide valuable information on drug
access to tumour tissue, which can be affected by a number
of factors such as the P-glycoprotein (PgP) and breast cancer
resistance protein (BCRP) [4, 5] drug efflux mechanisms
and aberrant tumour vasculature [6] (Table 1). Despite this
valuable tool, there have been no prospective studies which
used PET imaging for early decision-making in oncology
trials. Consequently, the full potential of such studies had not
been fully harnessed.
NMEs can be radiolabelled with short-lived positron-
emitting radioisotopes (e.g., carbon-11, half-life 20mins;
Fluorine-18, half-life 119mins) or with longer half-lives (e.g.,
Zirconium-89, half-life 3.3 days; Iodine-124, half-life 100
hours). Since the longer half-life of Zirconium-89 (89Zr) and
Iodine-124 (124I) matches the circulation half-lives of mono-
clonal antibodies (mAbs), theses isotopes have been used in
the radiolabelling and evaluation of mAbs (Immuno-PET).
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Table 1: Examples of some the clinical PET biodistribution studies performed with radiolabelled anticancer agents.
Drug References
5-Fluorouracil [10, 11]
Temozolomide [12, 13]
N-[(2󸀠-dimethylamino)ethyl]acridine-4-carboxamide (XR5000) [14, 15]
Antisense oligonucleotide to Survivin (LY2181308) [16, 17]
Docetaxel [18]
Paclitaxel [19]
Lapatinib [20]
Erlotinib [21–23]
Anti-CD44v6 chimeric monoclonal antibody, U36 [24]
Trastuzumab [25, 26]
Some radiolabelled molecular entities under evaluation in ongoing imaging studies (NIH trial database)
[
89Zr]-Bevacizumab, [89Zr]-RO5323441 (placental growth factor antibody), [18F]-SKI-249380 (dasatinib derivative), [124I]-PUH71,
MMOT0530A (a monoclonal antibody), [18F]-Paclitaxel, [11C]-Erlotinib, and [89Zr]-Cetuximab
Crucial developments including commercial availability of
89Zr and 124I, development and implementation of simplified
radiolabelling techniques, and availability of radiolabelling
protocols have allowed broad-scale clinical application of
89Zr- and 124I-immuno-PET in clinical mAb development
studies [7]. However, such radiolabelling methods are not
suited for other NMEs, which require development of
molecule-specific radiochemistry. Moreover, the higher radi-
ation doses associated with longer-lived PET radioisotopes
limit its use in healthy volunteers and in performing repeat
scans in the same subject.
In this paper, we have specifically focused on imaging
studies of NMEs radiolabelledwith short-lived radioisotopes.
We will discuss the barriers in the implementation of PET
studies, which currently limit the value of this tool. Using
an example, we outline the logistics involved in conducting
such studies. Finally, we propose ways to overcome potential
barriers to streamline the performance of PET imaging
studies with a particular emphasis on the conduct of such
studies in the United Kingdom (UK).
2. PET Imaging Studies with Radiolabelled
NMEs Are Ethically Justified and Provide
Potential Savings in Drug Development
Because approximately 92% of oncology NMEs will not be
approved [8], hundreds of patients receive limited or no
additional benefit from participating in trials with NMEs.
Incorporation of PET imaging studies in proof of concept
studies, such as First-in-Human Dose (FHD) studies, is
therefore a way to reduce attrition and is ethically justified,
because it may help exclude ineffective NMEs early. As only
8% of oncology drugs reach the market, there has been an
impetus to reduce late phase attrition by performing early
proof of concept studies [9]. Typically phase I FHD studies
are about a tenth (∼£ 10m) as expensive of a phase III study
(∼£ 100m) [8]. Therefore, if PET studies are able to support a
futility decision on aNME in a phase I proof of concept study,
it will allow the drug developer to shift focus to other active
NMEs. In the experience of the authors, the additional cost of
a typical PET study in 6 to 10 patients including development
of radiochemical synthesis methods, regulatory approvals,
and data analysis can range between £ 0.5 and 1 million. Such
studies may also reduce the number of subjects needed in a
FHD study and thus offset the costs of the imaging study. All
of the above may potentially lead to increased efficiency in
drug development and lead to a significant reduction in the
costs of drug development.
3. Pharmacological Information Obtained
from Clinical PET Studies
PET is a highly sensitive technology allowing the quantifi-
cation of picomolar tissue levels, thereby enabling studies to
be performed at microdoses of the NME, typically defined
as 1–100 𝜇g or <1/100 of the therapeutic dose. For instance,
microdose studies with the radiolabelled topoisomerases I
and II inhibitor, DACA, and [11C]DACA were performed
at 1/1000th of the phase I starting dose [14], a significant
advantage during early drug development. PET studies with
radiolabelled NMEs can provide information on drug phar-
macology and are especially valuable where standard phar-
macokinetic evaluation cannot be extrapolated from plasma
pharmacokinetic profile of the NME (e.g., brain). They can
also provide key information on the drug pharmacokinetics
when the NME has a complex structure and there is an
uncertainty about the pharmacokinetic profile and its impact
on the target site (e.g., antisense oligonucleotide; ASO). In
the following we show the primary benefits of using PET.
A potential caveat with PET pharmacokinetic studies with
agents administered orally may result due to differences in
bioavailability as PET studies are conducted with intravenous
administration of the radiolabelled NME.
3.1. Direct Evidence of Drug Access to Tumour Tissue.
PET studies can provide direct evidence of drug access
to target and the relative uptake in tumours compared to
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normal tissue. PET studies with radiolabelled temozolo-
mide ([11C]temozolomide) performed during early devel-
opment demonstrated higher uptake of [11C]temozolomide
in gliomas compared to normal brain tissue suggestive of
a potentially advantageous therapeutic index [12]; currently,
temozolomide is an approved and frequently used agent in
the routine management of brain tumours.
3.2. Access to Sanctuary Sites. In contrast to brain tumours or
metastases wherein the blood-brain-barrier is generally dis-
rupted, drug access to normal brain remains a challenge.This
is particularly an issue for monoclonal antibodies because
their size does not allow them to cross an intact blood-
brain-barrier and thereby fail to prevent CNS recurrences
[27]. Although small molecules may have improved brain
access due to their lower molecular weight, a number of
factors influence the penetration of small molecules to the
brain, such as lipophilicity, electric charge, affinity to active
transport systems, or being a substrate compound for drug
efflux mechanisms [28, 29]. Since there are limited models
able to predict blood-brain-barrier penetration, a clinical
PET study can provide direct confirmation. For example,
a recent study of radiolabelled lapatinib, a small molecule
targeting Her-1 and Her-2 tyrosine kinase, suggested that the
drug did not cross an intact blood-brain-barrier [20]. Such
an imaging study in small number of subjects can provide
important insights into the lack of access to a sanctuary site,
such as the brain, and thus avoid an expensive large trial or
help design an appropriate confirmatory clinical study.
3.3. Evidence of Target Engagement and Drug Activity. Target
engagement is crucial with the arrival of novel cytostatic
and targeted agents especially since conventional structural
imaging methods may not show a decrease in tumour size
despite target engagement. For instance, target engagement of
the anticancer agent LY2181308 as evidenced by the biodistri-
bution of [11C]LY2181308 in tumours was proven through an
associated decrease in tumour glucose metabolismmeasured
by FDG-PET uptake [16]. Such direct and early evidence of
target engagement could not have been substantiated in the
absence of a decrease in tumour size on CT readout [16].
While PET studies using an appropriate pharmacodynamic
radiotracer can provide an early readout of target engage-
ment, they can also suggest resistance and/or sensitivity
mechanisms, that is, discrepancy between tumour uptake
and response to treatment. Other PET pharmacodynamic
(PD) markers assess glucose metabolism (FDG), prolif-
eration (Fluorothymidine), perfusion (water), angiogenesis
(Fluciclatide) and hypoxia (fluoromisonidazole, HX4). The
appropriate use of such a PET PD biomarker is based on the
biology of the drug action and its presumed target.
3.4. Target Engagement for Patient Stratification. Poten-
tial differences in tumour phenotypic expression may be
exploited to help stratify and in personalisation of ther-
apy as elegantly exemplified by clinical PET studies with
[11C]erlotinib, a tyrosine kinase inhibitor of epidermal
growth factor receptor (EGFR). In patients with nonsmall
cell lung cancer, higher uptake of [11C]erlotinib was observed
in patients with exon 19 mutations compared to patients
with wild type EGFR expression, potentially allowing for
personalisation of therapy [21, 22]. There is an increasing
interest in the radiolabelling tyrosine kinase inhibitor (TKI)
to aid their clinical development as shown by studies with 7
of the 12 FDA-approved TKIs [30]. cMET is a protooncogene
that encodes a protein known as hepatocyte growth factor
receptor, whose abnormal activation in cancer correlates with
poor prognosis. A cMET imaging radioligand is also under
development that may be used to potentially identify cMET
positive tumours prior to administration of a cMET inhibitor
[31].
3.5. Indication of Normal Tissue Toxicity. PET studies can
also provide crucial information on the differential uptake
of the NME and its radiolabelled metabolites in various
tissue organs. Although the presence of increased drug
concentrations in normal tissue do not necessarily signify
specific tissue toxicities, increased uptake, and retention in
tissues such as the cardiac muscle, renal cortex, or the
presence of enterohepatic circulation of radioactivity may
alert to the need of a vigorousmonitoring andmanagement of
potential normal tissue toxicities during drug development.
Microdosing clinical studies with [11C]DACA, a drug that
did not progress beyond phase II studies, demonstrated
drug accumulation in the heart suggestive of a potential
cardiotoxicity risk, which in the later phase II studies was
fortunately not observed [32–34].
3.6. Drug Scheduling. PET studiesmay potentially help in the
optimisation of drug scheduling strategies that are intended
to maximize drug levels/exposure to the target tissue, while
limiting exposure to healthy organs. Such studies can be con-
ducted either during early or late drug development stages.
By applying mathematical techniques to PET studies with
[11C]temozolomide, it was possible to predict brain tumour
and normal tissue temozolomide concentration profiles for
different temozolomide dosing regimens [13]. This study
suggested that the predicted biodistribution of temozolomide
in tumour was better for the 200mg/m2/day for 5 days q 28
days regimen compared to 100mg/m2/day for 5 days q 28 days
and 75mg/m2/day for 7 weeks regimens, a finding consistent
with current clinical practice.
3.7. Utility of PET Biodistribution Studies in Later Phase
Clinical Development. Although in this paper we primar-
ily focused on the utility of PET imaging in FHD or
early proof of concept studies, information provided from
such studies can also be helpful in later phase trials, in
order to interrogate drug combinations, novel-novel-drug
testing, schedule modification, and repositioning of the
compound. Some of these studies are currently under way
(Table 1).
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4. Implementation Challenges for PET
Imaging Exemplified by the FHD Study
with Antisense Oligonucleotide (ASO)
(LY2181308) Targeting the Apoptosis
Inhibitor Protein Survivin
Having discussed the potential advantages of performing
PET studies with radiolabelled NMEs in FHD studies, we
shall now provide an overview of one such study illustrating
the challenges during early cancer drug development. This
is one of the few examples of an imaging study with a
radiolabelled NME which was prospectively integrated in a
FHD study [16].
4.1. Study Genesis and Aims. The compound, LY2181308 (Eli
Lilly and Company), was radiolabelled because there was
uncertainty onwhether such anASOwould reach the tumour
tissue. For such a biodistribution study, there were several
advantages for an ASO and in particular for LY2181308:
(a) the pharmacokinetics of the agent allowed a nearly full
extrapolation from animals to humans [17]; (b) the manufac-
turing was well controlled with few impurities. Importantly,
at the time of conception, there was neither pharmacokinetic
nor biodistribution study data for any ASO performed
in cancer patients; consequently additional information on
distribution of the ASO to the tumour was needed prior to
moving the NME into the next phase of clinical development.
Therefore, normal tissue and tumour pharmacokinetics of
this NMEwas determined and its antitumour effect in cancer
patients was assessed.
4.2. Operational Setup and Study Organisation. Broadly, the
process consisted of 3 main tasks (a) development of radi-
olabelling conditions to non-Good Manufacturing Practice
(non-GMP) standards and performance of preclinical radia-
tion dosimetry, (b) transfer of non-GMP radiochemistry to
GMP standard, tracer validation for clinical use, and submis-
sion of a dossier detailing radiochemical manufacturing and
quality control processes to theUKMedicines andHealthcare
Regulatory Agency (MHRA) for approval, and (c) submis-
sion of the clinical study documents to the independent
Research Ethics Committee (REC) and the Administration
of Radioactive Substances Committee (ARSAC) for approval
to conduct the study in cancer patients. This required mul-
tidisciplinary and multi-institutional collaborations between
the Early Oncology Clinical Investigation Division at Eli
Lilly and Company, the sponsor and owner of LY2181308,
and the University of Washington, St. Louis, MO, USA
(UW) for development of non-GMP radiochemistry and
the University of Manchester Wolfson Molecular Imaging
Centre, Manchester, UK (WMIC), for implementation of
GMP radiochemistry and conducting the clinical study.
The initial step to perform feasibility evaluation of
radiosynthesis of [11C]LY2181308 and development of non-
GMP production at UW took over 15 months. The time
period for this step is variable and will depend on the ease
of introduction of the PET isotope. The synthetic route to
label the NME often differs from that of the corresponding
unlabelled drug since the short half-life of the isotope
requires the radioisotope to be introduced as part of the final
synthetic step. This means both precursor for labelling and
the radiotracer may require development of their respective
preparation route. Dosimetry studies were then conducted
in nonhuman primates to estimate the human radiation
effective dose [35]. Following this, technology transfer of
the methods to WMIC was undertaken for implementation
of GMP radiochemistry. Implementation of GMP radio-
chemistry and performance of validation runs were done to
confirm the manufacturing and quality control processes of
the tracer in accordance with the approved EU regulations.
Validation runs were performed to ensure that the impurities
and additives in the end-product were within acceptable
levels for human administration and confirmed the sterility
of the formulated [11C]LY2181308 doses produced. Although
the formulated [11C]LY2181308 was going to be given to
patients participating in the concurrent FHD study, the
radioactive form of [11C]LY2181308 required a separate and
updated Investigational Medicinal Product Dossier (IMPD)
for this substudy of the FHD.This requirement was based on
the fact that [11C]LY2181308 was prepared and formulated in
a different way than the authorised drug product for the con-
current FHD study. The IMPD therefore included updates to
the Chemistry, Manufacturing and Control (CMC) section.
Medical sections had to also be updated in the IMPD for the
FHD study to justify the PET biodistribution study.
4.3. Study Hurdles. A number of considerable delays were
encountered as this was the first of its kind study at that
time (2005-2006) after introduction of the new regulatory
processes emanating from the EU clinical trial directive. The
major delay related to compiling adequate and sometimes
novel documentation for regulatory review. In the light of
new guidelines by the European Medicines Agency (EMEA)
(EMEA 2006; [36]), a formal site inspection for assessing the
manufacturing and production of the radiolabeled agent was
performed by the UK Medicines and Healthcare products
Regulatory Agency (MHRA) which added to the timelines.
In parallel to the MHRA submissions other regulatory sub-
missions to the Research Ethics Committee (REC) and the
Administration of Radioactive Substances Advisory Com-
mittee (ARSAC) were made. Delays were also encountered
with ethics approval as there were concerns about adminis-
tration of radioactivity and the REC was unfamiliar with this
type of study. Overall, the time from early radiochemistry
work and dosimetry studies to the initiation of the clinical
study took about 3 years (Figure 1).
4.4. Scientific Information Provided by the Study. Despite the
long wait, this study provided valuable information, demon-
strating rapid biodistribution of the radiopharmaceutical in
tissues (including the tumour), an unanticipated but positive
finding. In addition, greater than anticipated accumulation
of [11C]LY2181308 was observed in the cortex of kidneys, a
finding that differed from the preclinical data. Consequently,
there was concern about ASO-related renal toxicity and
this directed adequate monitoring strategies for phase II
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Preclinical toxicology
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approval
First-human dose
Dosimetry studies in
nonhuman
primates
Submission to
ARSAC
Process validation
at imaging center
∙ Sterility
assessment
∙ Reproducibility
Submission to
MREC
Update of EU CTA
databases in the
CM and C section
Quality agreement
sponsor/site
Third party oversight
MHRA
approval
Certification as
manufacturing site
MHRA
approval
Dosing
in
patients
safety study
(a)
Regulatory
approval First-human dose safety study
Preclinical toxicology
and other preparatory
studies
Stage I Stage II Stage III
∙ Setup of
confidentiality
agreements
and contracts
∙ Initial study
discussions
∙ Study teams
formation
∙ Radiochemistry
development and
implementation
∙ Animal
dosimetry
∙ Preclinical
toxicology
∙ Preparation,
submission of
regulatory
approval forms
∙ Protocol
development
∙ Identification
of clinical
collaborators
Initiation of PET biodistribution study
PET studies in patients to coincide with start
of FHD studies
PET biodistribution studies may be performed
in the dose escalation cohorts or in dose
expansion cohorts at the RPTD
1st year 2nd year
3rd year
(b)
Figure 1: Summary of timelines and procedures performed in the PET biodistribution study of the ASO LY2181308 in relation to the FHD
study (a). (b) Is proposed flowchart of future streamlined timelines of PET biodistribution studies in relation to FHD oncology studies with
NMEs.
studies. Incidentally, the FHD study with LY2181308 [16, 17]
included a patient in which the possible renal toxicity was of
concern [37]; fortunately, this grade 2 toxicity was not dose-
limiting and reversible. This unexpected finding during the
biodistribution study shows another advantage of conducting
such biodistribution studies early in drug development,
because it detected an otherwise unappreciated toxicity risk.
This study also demonstrated a decrease in tumour glucose
metabolism as observed by a decrease in FDG-PET uptake,
while simultaneously the target engagement was evaluated.
Complementing the otherwise favourable safety profile, this
concomitant tumour response and target engagement justi-
fied the advancement of LY2181308 into phase II development
[38–40].
5. Current Outlook and Future Considerations
Early drug development is a dynamic process with a focus
on timelines to ensure the delivery of NMEs to the next
development phase. Radiolabelling of an NME is often
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commissioned late within a drug lifecycle and the impact of
such data on key decisions can easily be lost. Delivery of a
radiolabelled NME study needs to focus on providing the
right data at the right time for the programme—andwe argue
that its greatest use is during early drug development.
Since the completion of the study with LY2181308, some
of the processes have been positively streamlined in the
UK. These include the implementation of the integrated
research application system (IRAS) that allows for parallel
submission to the various regulatory bodies including the
Research Ethics Committee (REC), ARSAC, MHRA, and
the hospital Research and Development (R&D) committees.
Despite this, we feel that regulatory processes can be further
streamlined in order to reduce timelines without sacrificing
quality and patient’s safety. For instance, although decisions
from regulatory bodies such as REC,MHRA, andARSAC are
dictated by strict timelines, addressing multiple queries from
RECs that either are unaware of or have not dealt with such
biodistribution studies with radiolabelled NMEs may result
in significant delays. Therefore, assignment of specialized
RECs to review such PET studies would likely minimise
delays.
In addition to the interaction with regulatory bodies,
recruitment of patients to PET studies is dependent on
the hospital R&D approval process, which is not time-
bound. Discussions with the hospital R&D departments can
lead to an impasse about study costs, extent of contractual
obligations, intellectual property (IP) rights, and other legal
interpretations of contracts. An early engagement with hos-
pital R&D departments and the clinical investigators and/or
mandating time-bound approval process may help reduce
delays. The European Commission has also recognised that
since the introduction of the EU Clinical Trials directive
2001/2/EC the number of clinical trial applications in the
EU between 2007 and 2011 has fallen by 25%, whilst the
costs for bureaucracy and resource requirements to handle
paperwork have doubled, and delays have increased by 90%.
The European Commission is therefore putting together
new proposals that will reduce bureaucracy and include
procedures to simplify and streamline the trial authorisation
procedures. We hope that these proposals likely to come into
effect in 2016 will improve the regulatory approval processes.
Currently PET clinical studies with radiolabelled NMEs
are considered a clinical trial by the MHRA, requiring
submission of an IMPD in the UK. As the MHRA now
regularly audit imaging centres for PET studies, it is no longer
a requirement that sites are reaudited before the initiation
of every such biodistribution study. Guidelines for animal
toxicity testing and for quality of all chemicals entering
the manufacturing process and of the radiopharmaceutical
(European commission GMP guidelines Annex 3, 2008 [41])
provide useful recommendations for the GMP implementa-
tion of radiopharmaceuticals for early phase clinical trials
[42]. However, time and resources to conduct additional
animal toxicology evaluation to enable PET imaging studies
are minimal and consideration is given to include such
studies in the standard animal toxicology evaluation if PET
studies are planned in order not to add further time to the
existing timelines.
Since animal dosimetry studies overestimate the radia-
tion dose in humans and the radiation exposure for carbon-11
radiotracers is quite low (on average equivalent to about one
year of background radiation exposure in the UK), we believe
that dosimetry studies are not required, especially for carbon-
11 labelled NMEs [43]. Even with Fluorine-18 radiolabelled
radiotracers, the radiation exposure to the subject is on
average similar to that obtained with a diagnostic FDG PET
scan (or equivalent to about 3-year background radiation
exposure) [44]; a case can bemade for not performing animal
dosimetry studies for radiolabelled NMEs, especially in a
group of patients with limited life span and where the tracer
is unlikely to be used as a diagnostic agent in the future.
Other processes may also lead to potential delays, includ-
ing those related to transference of non-GMP to GMPmeth-
ods. Radiolabelling feasibility of the NME and production of
the radiopharmaceutical with good reproducibility may be
highly variable. Hence, the feasibility evaluation processmust
consider the chemical structure and the ease of synthesis of
the NME. The performance of the labelling feasibility work
should be done on a similar automated platform as the one(s)
to be used for the GMP implementation. This requires an
appropriate PET radiochemistry infrastructure ideally with
duplication of equipment, as R&D gradematerials should not
be used on equipment forGMP synthesis in accordance to EU
guidelines. Involvement of the quality assurance department
early in the development process will also make for an easy
translation to the GMP settings. Finally, sourcing of a GMP-
grade precursor, failure of validation runs, and delays in
sterility analysis during validation may need to be addressed
to avoid potential delays.
Therefore, good project management including a GMP
implementation and risk management plan and regular
interaction between the drug developers, radiochemists, and
medicinal chemists during the development process will help
focus on the timelines and address unforeseen issues. Project
allocation to a team with expertise in R&D radiolabelling
feasibility and translation to GMP will especially help avoid
potential delays. Skilled leadership, effective communication
and decision-making, formation of study teams consisting
of members with the requisite skills, and identification of
favoured suppliers to source precursors are likely to help
prevent delays.
As the ultimate success of such studies is crucially depen-
dent on patient recruitment, protocols should be patient-
friendly. It is equally important that the small number of
imaging centres work closely with the FHD study sites
and the clinical investigators. Therefore, a well-established
nexus of the imaging centre, phase I units, and clinical
investigators that can deliver such studies will be attractive
to the pharmaceutical industry.
On the basis of our experience, a period of up to 6
months is expected from initiation of a study proposal to
confirmation of radiochemistry production feasibility. An
additional 9 months is then required for the implementation
of radiolabelling methods in accordance with the principles
of GMP, regulatory submission, and approval until the
initiation of the PET biodistribution study (Table 2). This
period of 15months for initiation of the PET study from study
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Table 2: Sequential stages of activities, their timelines, potential causes for delays, and recommendations to reduce delays in PET
biodistribution studies.
Activities Approx. time(months) Potential causes for delays
Comments and recommendations
for improvement in timelines
Stage I (all activities can be done simultaneously): time 1-2 months
Initial study discussion formulation
of an outline research plan 2 months
Prevarication, and absence of key
decision makers
Clear communication and clear goal
setting by the respective team
leaders
Confidentiality agreements
completion 1-2 months Legal issues
Preexistence of a master services
agreements
Formation of study teams with clear
definition of roles and
responsibilities
1 month
Organisational issues
Availability of experienced staff and
agreement
Ensure inclusion of key staff,
chemists, regulatory, clinical,
biologists
Contract agreements 1-2 months Disagreements on pricing andintellectual property rights
Early finance and legal involvement.
Work with contract-based imaging
services providers
Stage II (all activities can be done simultaneously): time 4–7 months
Radiochemistry feasibility and
production of radiolabelled NME
(non-GMP or GMP)
Implementation of GMP
radiochemistry (RC) and its
validation
Preclinical dosimetry study
Animal toxicology studies
4–7 months
Radiochemical method
development issues
Issues with procurement of
precursor (GMP or non-GMP)
Problems transferring from
non-GMP to GMP settings
Selection of PET centre with good
track record of developing and
implementing
radiopharmaceuticals for clinical
use and management of drug maker
expectations
Preferred approved suppliers
Duplication of equipment for
straightforward transfer of methods,
development of cassette based
chemistry, good communication,
and regular interactions
Agreement of clear milestones and
associated timelines for “Go-No
Go” decisions
Stage III (all activities can be done simultaneously): time 3–6 months
Preparation of IMPD dossier for
submission to MHRA 1 month
Subject to delays in GMP
implementation
Experienced personnel to complete
CMC section
Identification of clinical
collaborators
Initiation of contracts with hospital
3 months
Identification and selection of
appropriate clinicians
Realistic assessment of recruiting
potential
Initiate early in Stage III as can
cause significant delays
Preferred clinicians, imaging
centre-linked clinical units
Development of research study
protocol 2 months
Internal hierarchical and regulatory
approval
Preparation and submission of
regulatory submission to the REC,
MHRA, and ARSAC and to hospital
R and D
2 months
CMC section completion due to RC
implementation delays
Delays in getting a date for an REC
meeting
Done via the common IRAS
However, MHRA and ARSAC
require additional information to
that provided by IRAS
Obtaining regulatory approvals and
study initiation 2-3 months
Delays if there are queries or need
for modifications
Variable calibre of ethics committee
to review such studies
Hospital R and D approval not
time-bound
Submission to or designation of
ethics committees to review such
studies
conception would fit well with the similar time required for
standard initiation of a FHD clinical study from compound
selection. We think that these streamlined timelines would
allow for a greater integration of PET biodistribution studies
during FHD clinical studies.
Despite the potential utility, anticipated improvements
of organisational and regulatory interactions, and increased
interest in radiolabelling NMEs [45], there is a missing
collection of examples supporting the value for early clinical
biodistribution studies. This lack of supporting information,
perceived high costs, timelines, and overall complexity of the
technology [46], in a current climate of tightening budgets,
prevents us from fully assessing the impact of biodistribution
studies on clinical development and hampers uptake by
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scientists and clinicians intimately involved in the drug
development process. However, it is heartening to note that
there are a few clinical PET biodistribution studies currently
underway worldwide, as reflected in the NIH trial database
(Table 1). While from this list it appears that NMEs are being
evaluated in imaging studies, their value in the overall drug
development is not clear. Nevertheless, we anticipate that
results from such and other well-designed studies integrated
into the drug development process will likely catalyse a wider
use of this technology and an even greater focus on efficiency
and timelines.
We would like to propose the following action points
that would lead to greater implementation of such studies.
Firstly, the key stakeholders from academia, industry, PET
community, and imaging bodies should be brought together
to act as a forum for discussion of proposals submitted
by members who are new to this area. We envisage that
this group would provide advice and guide in the setup
and implementation of studies and also interact with the
regulatory bodies. Because such specialized clinical imaging
centres are limited, we would propose creating a network of
accredited centres working closely with clinical investigators
and clinical units that are able to implement all aspects of
such studies. At the current stage, we do not expectmore than
5 such studies to occur every year worldwide; however, this
would likely increase if such studies prove their value in drug
development.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
References
[1] M. Bergstro¨m, A. Grahne´n, and B. La˚ngstro¨m, “Positron emis-
sion tomography microdosing: a new concept with application
in tracer and early clinical drug development,”European Journal
of Clinical Pharmacology, vol. 59, no. 5-6, pp. 357–366, 2003.
[2] S. Kapur, R. Zipursky, C. Jones, G. Remington, and S.
Houle, “Relationship between dopamineD2 occupancy, clinical
response, and side effects: a double-blind PET study of first-
episode schizophrenia,”TheAmerican Journal of Psychiatry, vol.
157, no. 4, pp. 514–520, 2000.
[3] P. M. Matthews, E. A. Rabiner, J. Passchier, and R. N. Gunn,
“Positron emission tomography molecular imaging for drug
development,” British Journal of Clinical Pharmacology, vol. 73,
no. 2, pp. 175–186, 2012.
[4] K. Natarajan, Y. Xie, M. R. Baer, and D. D. Ross, “Role of
breast cancer resistance protein (BCRP/ABCG2) in cancer drug
resistance,” Biochemical Pharmacology, vol. 83, no. 8, pp. 1084–
1103, 2012.
[5] R. K. Vadlapatla, A. D. Vadlapudi, D. Pal, and A. K. Mitra,
“Mechanisms of drug resistance in cancer chemotherapy:
coordinated role and regulation of efflux transporters and
metabolizing enzymes,” Current Pharmaceutical Design, vol. 19,
no. 40, pp. 7126–7140, 2013.
[6] A. Saleem and P.M. Price, “Early tumor drug pharmacokinetics
is influenced by tumor perfusion but not plasma drug expo-
sure,” Clinical Cancer Research, vol. 14, no. 24, pp. 8184–8190,
2008.
[7] G. A. M. S. Van Dongen and M. J. W. D. Vosjan, “Immuno-
positron emission tomography: shedding light on clinical anti-
body therapy,” Cancer Biotherapy and Radiopharmaceuticals,
vol. 25, no. 4, pp. 375–385, 2010.
[8] S. M. Paul, D. S. Mytelka, C. T. Dunwiddie et al., “How
to improve R&D productivity: the pharmaceutical industry’s
grand challenge,” Nature Reviews Drug Discovery, vol. 9, no. 3,
pp. 203–214, 2010.
[9] B. Pagliara, “A record year for approvals,”MedNous, vol. 7, no. 2,
pp. 6–8, 2012.
[10] E. O. Aboagye, A. Saleem, V. J. Cunningham, S. Osman, and
P. M. Price, “Extraction of 5-fluorouracil by tumor and liver:
a noninvasive positron emission tomography study of patients
with gastrointestinal cancer,”Cancer Research, vol. 61, no. 13, pp.
4937–4941, 2001.
[11] A. Saleem, J. Yap, S. Osman et al., “Modulation of fluorouracil
tissue pharmacokinetics by eniluracil: in-vivo imaging of drug
action,”The Lancet, vol. 355, no. 9221, pp. 2125–2131, 2000.
[12] A. Saleem, G. D. Brown, F. Brady et al., “Metabolic activation
of temozolomide measured in vivo using positron emission
tomography,” Cancer Research, vol. 63, no. 10, pp. 2409–2415,
2003.
[13] L. Rosso, C. S. Brock, J. M. Gallo et al., “A new model for
prediction of drug distribution in tumor and normal tissues:
Pharmacokinetics of temozolomide in glioma patients,” Cancer
Research, vol. 69, no. 1, pp. 120–127, 2009.
[14] A. Saleem, R. J. Harte, J. C. Matthews et al., “Pharma-
cokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-
4-carboxamide in patients by positron emission tomography,”
Journal of Clinical Oncology, vol. 19, no. 5, pp. 1421–1429, 2001.
[15] D. J. Propper, J. De Bono, A. Saleem et al., “Use of positron
emission tomography in pharmacokinetic studies to investigate
therapeutic advantage in a phase I study of 120-hour intra-
venous infusion XR5000,” Journal of Clinical Oncology, vol. 21,
no. 2, pp. 203–210, 2003.
[16] A. Saleem, J. C.Matthews,M.Ranson et al., “Molecular imaging
and pharmacokinetic analysis of carbon-11 labeled antisense
oligonucleotide LY2181308 in cancer patients,”Theranostics, vol.
1, pp. 290–301, 2011.
[17] D. C. Talbot, M. Ranson, J. Davies et al., “Tumor survivin is
downregulated by the antisense oligonucleotide LY2181308: a
proof-of-concept, first-in-human dose study,” Clinical Cancer
Research, vol. 16, no. 24, pp. 6150–6158, 2010.
[18] A. A. M. van der Veldt, N. H. Hendrikse, E. F. Smit et al., “Bio-
distribution and radiation dosimetry of 11C-labelled docetaxel
in cancer patients,” European Journal of Nuclear Medicine and
Molecular Imaging, vol. 37, no. 10, pp. 1950–1958, 2010.
[19] K. A. Kurdziel, J. D. Kalen, J. I. Hirsch et al., “Human dosimetry
and preliminary tumor distribution of 18F- fluoropaclitaxel in
healthy volunteers and newly diagnosed breast cancer patients
using PET/CT,” Journal of Nuclear Medicine, vol. 52, no. 9, pp.
1339–1345, 2011.
[20] A. Saleem, “Brain and tumor penetration of carbon-11–la-
beled lapatinib ([11C]Lap) in patients (pts) with HER2-over-
expressing metastatic breast cancer (MBC): ASCO Annual
Meeting 2013, Chicago, USA,” Journal of Clinical Oncology, vol.
31, supplement, abstract 635, 2013.
The Scientific World Journal 9
[21] I. Bahce, E. F. Smit, M. Lubberink et al., “Development of
[11C]erlotinib positron emission tomography for in vivo eval-
uation of EGF receptor mutational status,” Clinical Cancer
Research, vol. 19, no. 1, pp. 183–193, 2013.
[22] D. J. Stewart and J. J. Erasmus, “Erlotinib accumulation in
brain metastases from non-small cell lung cancer: visualization
by positron emission tomography in a patient harboring a
mutation in the epidermal growth factor receptor,” Journal of
Thoracic Oncology, vol. 6, no. 7, pp. 1149–1151, 2011.
[23] A. A. Memon, B. Weber, M. Winterdahl et al., “PET imaging
of patients with non-small cell lung cancer employing an EGF
receptor targeting drug as tracer,” British Journal of Cancer, vol.
105, no. 12, pp. 1850–1855, 2011.
[24] P. K. E. Bo¨rjesson, Y. W. S. Jauw, R. De Bree et al., “Radiation
dosimetry of 89Zr-labeled chimeric monoclonal antibody U36
as used for immuno-PET in head and neck cancer patients,”
Journal of Nuclear Medicine, vol. 50, no. 11, pp. 1828–1836, 2009.
[25] E. C. Dijkers, T. H. O. Munnink, J. G. Kosterink et al., “Biodis-
tribution of 89Zr-trastuzumab and PET imaging of HER2-
positive lesions in patients with metastatic breast cancer,”
Clinical Pharmacology and Therapeutics, vol. 87, no. 5, pp. 586–
592, 2010.
[26] J. E. Mortimer, J. R. Bading, D. M. Colcher et al., “Functional
imaging of human epidermal growth factor receptor 2-positive
metastatic breast cancer using (64)Cu-DOTA-trastuzumab
PET,” Journal of Nuclear Medicine, vol. 55, no. 1, pp. 23–29, 2014.
[27] J. C. Bendell, S. M. Domchek, H. J. Burstein et al., “Central
nervous systemmetastases inwomenwho receive trastuzumab-
based therapy for metastatic breast carcinoma,” Cancer, vol. 97,
no. 12, pp. 2972–2977, 2003.
[28] N. J. Abbott, A. A. Patabendige, D. E. Dolman, S. R. Yusof, and
D. J. Begley, “Structure and function of the blood-brain barrier,”
Neurobiology of Disease, vol. 37, no. 1, pp. 13–25, 2010.
[29] R. Nau, F. So¨rgel, and H. Eiffert, “Penetration of drugs through
the blood-cerebrospinal fluid/blood-brain barrier for treatment
of central nervous system infections,” Clinical Microbiology
Reviews, vol. 23, no. 4, pp. 858–883, 2010.
[30] P. Slobbe, A. J. Poot, A. D. Windhorst, and G. A. M. S. Van
Dongen, “PET imaging with small-molecule tyrosine kinase
inhibitors: TKI-PET,” Drug Discovery Today, vol. 17, no. 21-22,
pp. 1175–1187, 2012.
[31] O¨. Lindhe, A. Thibblin, G. Antoni et al., “PET imaging of c-
Met expression in non-human primates using [18F]AH113804,”
in Proceedings of the 103rd Annual Meeting of the American
Association for Cancer Research, Chicago, Ill, USA, 2012.
[32] C.Dittrich, V.Dieras, P. Kerbrat et al., “Phase II study of XR5000
(DACA), an inhibitor of topoisomerase I and II, administered
as a 120-h infusion in patients with advanced ovarian cancer,”
Investigational New Drugs, vol. 21, no. 3, pp. 347–352, 2003.
[33] C. Dittrich, B. Coudert, L. Paz-Ares et al., “Phase II study
of XR 5000 (DACA), an inhibitor of topoisomerase I and II,
administered as a 120-h infusion in patients with non-small cell
lung cancer,” European Journal of Cancer, vol. 39, no. 3, pp. 330–
334, 2003.
[34] F. Caponigro, C. Dittrich, J. B. Sorensen et al., “Phase II study of
XR 5000, an inhibitor of topoisomerases I and II, in advanced
colorectal cancer,” European Journal of Cancer, vol. 38, no. 1, pp.
70–74, 2002.
[35] C. S. Dence, R. Laforest, X. Sun, T. L. Sharp, M. J. Welch, and
R. H. MacH, “Radiochemical synthesis, rodent biodistribution
and tumor uptake, and dosimetry calculations of [11C] methy-
lated LY2181308,”Molecular Imaging and Biology, vol. 12, no. 6,
pp. 608–615, 2010.
[36] European Medicines Agency, Guideline on the Requirements
to the Chemical and Pharmaceutical Quality Documentation
Concerning Investigational Medicinal Products in Clinical Trials,
European Commission, London, UK, 2006, Edited by Commit-
tee for Medicinal Products for Human Use (CHMP).
[37] W. G. Herrington, D. C. Talbot, M. M. Lahn et al., “Asso-
ciation of long-term administration of the survivin mRNA-
targeted antisense oligonucleotide LY2181308 with reversible
kidney injury in a patient withmetastaticmelanoma,”American
Journal of Kidney Diseases, vol. 57, no. 2, pp. 300–303, 2011.
[38] H. P. Erba, H. Sayar, M. Juckett et al., “Safety and pharmacoki-
netics of the antisense oligonucleotide (ASO) LY2181308 as a
single-agent or in combination with idarubicin and cytarabine
in patients with refractory or relapsed acute myeloid leukemia
(AML),” Investigational New Drugs, vol. 31, no. 4, pp. 1023–1034,
2013.
[39] P. Wiechno et al., “Randomized phase II study with window-
design to evaluate anti-tumor activity of the survivin anti-
sense oligonucleotide (ASO) LY2181308 in combination with
docetaxel for first-line treatment of castrate-resistant prostate
cancer (CRPC),” in Proceedings of the American Soceity of
ClinicalOncologyAnnualMeeting, Journal ofClinicalOncology,
Chicago, Ill, USA, 2013.
[40] D. Talbot, F. H. Blackhall, D. Kowalski et al., “A randomized
open-label phase II study evaluating antitumor activity of the
survivin antisense oligonucleotide LY2181308 (LY) in combina-
tion with docetaxel (DO) for second-line treatment of patients
with non-small cell lung cancer (NSCLC) using change in
tumor size (CTS),” in Proceedings of the American Soceity of
Clinical Oncology, Chicago, Ill, USA, 2013.
[41] E. A. I. Directorate-General, EU Guidelines to Good Medical
Practice Medicianl Products for Human amd Veterinary Use,
Edited by: C. G. Pharmaceuticals, European Commission,
Brussels, Belgium, 2008.
[42] A. Verbruggen, H. H. Coenen, J. Deverre et al., “Guideline
to regulations for radiopharmaceuticals in early phase clinical
trials in the EU,” European Journal of Nuclear Medicine and
Molecular Imaging, vol. 35, no. 11, pp. 2144–2151, 2008.
[43] P. Zanotti-Fregonara and R. B. Innis, “Suggested pathway to
assess radiation safety of11C-labeled PET tracers for first-in-
human studies,” European Journal of Nuclear Medicine and
Molecular Imaging, vol. 39, no. 3, pp. 544–547, 2012.
[44] P. Zanotti-Fregonara, A. A. Lammertsma, and R. B. Innis, “Sug-
gested pathway to assess radiation safety of 18F-labeled PET
tracers for first-in-human studies,” European Journal of Nuclear
Medicine and Molecular Imaging, vol. 40, no. 11, pp. 1781–1783,
2013.
[45] A. J. Poot, P. Slobbe, N. H. Hendrikse, A. D. Windhorst, and G.
van Dongen, “Imaging of TKI-target interactions for personal-
ized cancer therapy,” Clinical Pharmacology and Therapeutics,
vol. 93, no. 3, pp. 239–241, 2013.
[46] T. Jones, P. Price, and B. Tavitian, “Realizing the full potential
of PET for measuring the biodistribution of novel anticancer
agents,” Journal of Nuclear Medicine, vol. 52, no. 9, p. 1500, 2011.
